Targeted Interference with Signal Transduction Events: 172 - Rilegato

Rilegato

ISBN 10: 3540312080 ISBN 13: 9783540312086

Casa editrice: Springer Verlag, 2007

Riassunto

This book does nothing less than lay out the state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities. The sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to derive more efficient cancer drugs?

Su questo libro

Contenuti

Identifying critical signaling molecules for the treatment of cancer. Tyrosine kinase inhibitors and cancer therapy. Targeting ERBB receptors in cancer. Inhibition of the IGF-I receptor for treatment of cancer: kinase inhibitors and monoclonal antibodies as alternative approaches. Inhibition of the TGF-ß signaling pathway in tumor cells. The mammalian target of rapamycin kinase (mTOR) and tumor growth inhibition. The Ras signaling pathway as a target in cancer therapy. The mitogen activated protein kinase pathway for molecular-targeted cancer treatment. The function and the inhibition of the c-SRC gene in tumor cells.

Product Description

Book by None

Dettagli dell'edizione

• Editore: Springer Verlag
• Data di pubblicazione: 2007
• Lingua: Inglese
• ISBN 10: 3540312080
• ISBN 13: 9783540312086
• Rilegatura: Copertina rigida
• Numero edizione: 1
• Numero di pagine: 188
• Redattore: Groner B.
• Contatto del produttore: non disponibile
• Persona responsabile: Springer Nature Customer Service Center GmbH; ProductSafety@springernature.com; ; Europaplatz 3; Heidelberg; 69115; Germania